Anthony S. Marucci Buys 11,500 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci bought 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the purchase, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Celldex Therapeutics Stock Down 0.6 %

Shares of CLDX stock opened at $26.84 on Thursday. Celldex Therapeutics, Inc. has a 12 month low of $24.43 and a 12 month high of $53.18. The company has a market cap of $1.78 billion, a PE ratio of -10.67 and a beta of 1.60. The business’s 50 day moving average is $33.00 and its two-hundred day moving average is $35.66.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Novo Holdings A S boosted its holdings in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after acquiring an additional 113,663 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after purchasing an additional 2,664,915 shares during the last quarter. Swiss National Bank lifted its position in shares of Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after purchasing an additional 17,300 shares during the last quarter. Bellevue Group AG lifted its position in shares of Celldex Therapeutics by 15.7% during the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock worth $117,374,000 after purchasing an additional 380,319 shares during the last quarter. Finally, AlphaCentric Advisors LLC lifted its position in shares of Celldex Therapeutics by 23.4% during the 2nd quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company’s stock worth $1,758,000 after purchasing an additional 9,000 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on CLDX. Citigroup began coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, November 7th. The Goldman Sachs Group started coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.